Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Trial record 5 of 1422 for:    "Parkinson's Disease"

Efficacy of Transdermal Nicotine, on Motor Symptoms in Advanced Parkinson's Disease (NICOPARK2)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier:
NCT00873392
First received: March 31, 2009
Last updated: December 29, 2013
Last verified: December 2013
  Purpose

Medical treatment of idiopathic Parkinson disease motor symptoms requires dopaminergic drugs, with long term disabling side effects. (fluctuations, dyskinesia, ON/OFF phenomena). Use of nicotine in Parkinson's disease has been suggested by the lowest prevalence of smokers among Parkinsonian patients. However, controlled studies provided conflicting results. One of our patients showed a substantial decrease of his parkinsonian symptoms under transdermal nicotine-therapy. Currently, this patient has been treated since 8 years with an excellent safety, especially on cardiovascular level. Otherwise, the investigators performed an open pilot safety and feasibility study in 6 patients, which demonstrated the possibility of a controlled study. In this study, all patients received daily doses during several months until 105 mg/day and could, in parallel, decrease their L-Dopa and agonists doses, improving their motor scores.

The investigators now propose a phase II, controlled, single blind and randomised efficacy study (n=40) in 2 parallel groups. (1 group transdermal nicotine-therapy / 1 control group without additional therapy) The main objective is to verify the correlation between UPDRS (score III) motor score and the administrated nicotine dose. This study will also allow the evaluation of nicotine neuroprotective effect. The incrementation phase by weekly steps of 5 mg until 20 mg, then 10 mg to reach 90 mg/j or the maximal tolerated dose, will last on 11 weeks and will be followed by a 28 weeks phase at this stable dose. After this maximal dose "plateau phase", treatment will be progressively decreased by 15 mg weekly steps, over a de 6-week period followed by a five-week wash out phase.

Taking into account results from the pilot study, a long-term high doses treatment, seems to be liable to improve patients who deeply suffer from their disease. This is why the investigators now propose this monocentric institutional project.


Condition Intervention Phase
Idiopathic Parkinson's Disease
Drug: Transdermal nicotine
Other: Usual drug treatment of Parkinson's disease
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Efficacy of Transdermal Nicotine, on Motor Symptoms in Advanced Parkinson's Disease(One Daily Administration).A Controlled Randomised Study, in Two Parallel Groups and Single Blind in 40 Patients.

Resource links provided by NLM:


Further study details as provided by Assistance Publique - Hôpitaux de Paris:

Primary Outcome Measures:
  • Comparison of motor scores in defined off condition : UPDRS III motor score assessed in "defined OFF" condition in comparison with control group. [ Time Frame: after 20/39 weeks of treatment at maximal administered dose of nicotine ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Evaluation of UPDRS III motor score assessed in "defined OFF" condition [ Time Frame: after 20 weeks of treatment in comparison with control group ] [ Designated as safety issue: No ]
  • Improvement of UPDRS III motor score assessed in "defined ON" condition [ Time Frame: after a 12 hours discontinuation of antiparkinsonian treatments after 11, 20 and 39 weeks of treatment ] [ Designated as safety issue: No ]
  • Evaluation of motor benefit (UPDRS "OFF" and "ON") [ Time Frame: after a 28 weeks treatment period at stable dose of 90 mg ] [ Designated as safety issue: No ]
  • Evaluation of neuroprotection, (SPECT DaTSCAN and UPDRS "OFF") [ Time Frame: after 5 weeks of study treatment discontinuation ] [ Designated as safety issue: No ]
  • Persistence of motor benefit (UPDRS "OFF" and "ON") [ Time Frame: after 5 weeks of study treatment discontinuation ] [ Designated as safety issue: No ]
  • Decrease of total daily L-Dopa dose (or calculated equivalent in case of polytherapy) [ Time Frame: after 20 and 39 weeks of treatment ] [ Designated as safety issue: No ]
  • Improvement of quality of life (ADL and PDQ 39 scales) [ Time Frame: after 20 and 39 weeks of treatment ] [ Designated as safety issue: No ]
  • Decrease of daily percentage of "OFF" phase [ Time Frame: after 20 and 39 weeks of treatment ] [ Designated as safety issue: No ]
  • Improvement of dyskinesia score, (UPDRS IV) [ Time Frame: during the study ] [ Designated as safety issue: No ]
  • Relation dose / effect of nicotine [ Time Frame: end of the study ] [ Designated as safety issue: No ]
  • Estimation of the most effective and tolerated dose of nicotine per kg [ Time Frame: end of the study ] [ Designated as safety issue: No ]
  • Improvement of cognitive functions assessed by Mattis scale [ Time Frame: after 39 weeks of treatment ] [ Designated as safety issue: No ]
  • Comparison of all parameters between the 2 groups of patients [ Time Frame: after study treatment discontinuation, (Week 50) ] [ Designated as safety issue: No ]
  • Compliance to nicotine treatment [ Time Frame: during treatment ] [ Designated as safety issue: No ]
  • Tolerance of transdermal nicotine [ Time Frame: during the treatment ] [ Designated as safety issue: Yes ]

Enrollment: 40
Study Start Date: February 2009
Study Completion Date: May 2013
Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Experimental drug
Drug: Transdermal nicotine
Steps of 5 mg until 20 mg Then steps of 10 mg until the dose of 90mg or the maximal tolerated dose One stable dose phase, (90 mg or maximal tolerated dose) during 28 weeks
Other Name: Transdermal nicotine
Active Comparator: 2
Usual treatment
Other: Usual drug treatment of Parkinson's disease
Usual drug treatment of Parkinson's disease
Other Name: Usual drug treatment of Parkinson's disease

Detailed Description:

Experimental plan

Phase II controled study, in 40 patients, randomised in single blind, and in 2 groups:

  • One group treated by transdermal nicotine-therapy (N= 20),
  • One group without additional therapy (N= 20).

This study will consist in :

  • One phase of weekly incrementations of dose during 11 weeks,

    • Steps of 5 mg until 20 mg
    • Then steps of 10 mg until the dose of 90mg or the maximal tolerated dose
  • One stable dose phase, (90 mg or maximal tolerated dose) during 28 weeks,
  • One phase of decrementing: treatment will be progressively decreased in a 6 weeks period,
  Eligibility

Ages Eligible for Study:   35 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with idiopathic Parkinson's disease according to the United Kingdom Parkinson's Disease Society Brain Bank (UKPDSBB), since at least three years,or treated by L-dopa for 2 years minimum with motor fluctuations (amendment 12/10/2010)
  • Patients aged between 35 and 70 years inclusive,
  • L-Dopa responders: L-Dopa test with an improvement of over 30 % of UPDRS-III motor score,
  • L-Dopa treatment since at least three years,
  • Patients with Parkinson's disease stage maximum IV ("OFF" state) according to the modified Hoehn and Yahr classification (without treatment since at least 12 hours), and III maximum in "ON" state,
  • Non smoker,
  • Signed Informed Consent

Exclusion Criteria:

  • Previous neurosurgery for Parkinson's disease,
  • Weight < 45 kg or > 100 kg,
  • Previous Parkinson's disease treatment by transdermal nicotine-therapy discontinued less than 6 months before inclusion,
  • History of allergy to Nicotine,
  • History of allergy to transdermal device,
  • Cutaneous disorders wich could disturb use of transdermal device,
  • Cognitive disorders, (Mattis score < 125)
  • History or detection at inclusion of cardiac arrhythmia,
  • History of coronary failure,
  • History of cardiac failure, (NYHA from II to IV & ejection fraction (EF) < 40%)
  • Severe arterial hypertension (diastolic > 100 mmHg) or uncontrolled,
  • Symptomatic orthostatic hypotension, (2 points of differential in standing position and systolic <100mm Hg or clinical evidence)
  • History of stroke or occlusive peripheral vascular disease,
  • History of hyperthyroid,
  • History or detection at inclusion of type I or II diabetes, (HbA1c < 11%)
  • History of pulmonary disease: asthma, chronic obstructive pulmonary disease (COPD),
  • History of auto-immune disease,
  • Progressive depression, suicide attack, acute psychosis, invasive hallucinations, psychiatrist opinion harmful for a correct compliance to experimentation,
  • History or recent gastroduodenal ulcer, (< 3 months)
  • History or detection at inclusion of hepatobiliary or renal failure, (clearance< 60 mL/min)
  • Pregnancy, breast-feeding,
  • Absence of effective contraception in women in childbearing potential,
  • Treatment by nifedipine, beta-blockers, diuretics, insulin and H2 antihistaminics for potential side effects in combination with nicotine,
  • Patients unlikely to be compliant or to fully cooperate during the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00873392

Locations
France
Groupe Hospitalier Albert Chenevier Henri Mondor
Creteil, France, 94000
Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris
Investigators
Principal Investigator: Pierre CESARO, PUPH Groupe Hospitalier Albert Chenevier Henri Mondor
  More Information

Publications:
Responsible Party: Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier: NCT00873392     History of Changes
Other Study ID Numbers: P 051031
Study First Received: March 31, 2009
Last Updated: December 29, 2013
Health Authority: France: Ministry of Health

Keywords provided by Assistance Publique - Hôpitaux de Paris:
Parkinson's disease
Motor fluctuation
Nicotine
Drug treatment
neuroprotection

Additional relevant MeSH terms:
Parkinson Disease
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Movement Disorders
Nervous System Diseases
Neurodegenerative Diseases
Parkinsonian Disorders
Nicotine
Autonomic Agents
Cholinergic Agents
Cholinergic Agonists
Ganglionic Stimulants
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Nicotinic Agonists
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on November 27, 2014